がん生検の世界市場

がん生検の世界市場は2030年までに509億米ドルに達する見込み

2024年に290億米ドルと推定されるがん生検の世界市場は、2024年から2030年にかけてCAGR 9.8%で成長し、2030年には509億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである器具は、CAGR 8.6％を記録し、分析期間終了時には140億米ドルに達すると予測されます。キット＆消耗品セグメントの成長率は、分析期間でCAGR 8.4％と推定されます。

米国市場は79億米ドル、中国はCAGR13.2％で成長予測

米国のがん生検市場は、2024年に79億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに102億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは13.2%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ7.2%と8.5%と予測されています。欧州では、ドイツがCAGR 7.7%で成長すると予測されています。

世界のがん生検市場- 主要動向と促進要因のまとめ

なぜがん生検は正確な診断と個別化治療に不可欠なのか？

がん生検は現代の腫瘍学において重要な処置であり、がんの診断、腫瘍のタイプ、病期、悪性度の決定、個別化された治療計画を導くための決定的な方法として機能しています。生検では、疑わしい腫瘤から組織や細胞を採取し、顕微鏡検査によって悪性腫瘍を検出し、特定の分子マーカーを評価します。この診断プロセスにより、がんの存在が確認されるだけでなく、腫瘍の生物学的挙動や遺伝子プロファイルに関する重要な洞察が得られます。がん治療が標的療法や免疫療法へとますますシフトする中、正確な生検データはさらに不可欠なものとなっています。医師は、個人の腫瘍の特徴に基づいて最も効果的な治療プロトコルを選択し、治療が適切かつより成功する可能性を確実にするために、生検の結果を頼りにしています。生検がなければ、治療の決定は画像診断と症状のみに基づいて行われることが多く、結論が出なかったり、誤解を招いたりする可能性があります。さらに、生検は治療効果をモニターし、がんの再発を検出するために頻繁に使用され、長期的な患者管理の要となっています。病理学、画像誘導技術、分子検査などの進歩により、生検の精度と安全性は著しく向上しています。人口の高齢化、ライフスタイルの変化、環境暴露などにより、がんの罹患率が世界的に上昇する中、生検による早期かつ正確な診断の必要性はますます緊急性を増しており、生検は一連のがん治療におけるかけがえのない要素としての役割を強めています。

技術革新は生検技術と診断精度をどのように変革しているのか？

がん生検の分野は、精度を高め、侵襲を最小限にし、リアルタイム診断を可能にする技術的進歩の波によって革命的に変化しています。最も重要な開発の一つは、超音波ガイド下生検、CTガイド下生検、MRIガイド下生検などの画像ガイド下生検技術の台頭です。これらの方法は、最も代表的な組織を確実に採取することで、手技のリスクを軽減し、診断の歩留まりを向上させる。循環腫瘍DNA（ctDNA）、循環腫瘍細胞（CTC）、血液やその他の体液中のエクソソームなどのバイオマーカーを分析するリキッドバイオプシーの成長も大きな革新です。この非侵襲的アプローチにより、組織を繰り返し採取することなく、早期発見、治療反応の動的モニタリング、耐性変異の同定が可能になります。次世代シークエンシング（NGS）やその他の分子プロファイリングツールも、生検サンプルの解析方法を変えつつあり、腫瘍の包括的なゲノムマッピングを可能にし、精密治療に役立つ実用的な変異を発見することができます。ロボットやAIが支援する生検装置も登場し始めており、標的の絞り込みが改善され、オペレーターによるばらつきが減少しています。さらに、デジタル病理学は生検スライドのレビューを合理化し、より迅速な診断、遠隔診察、がんセンター間のデータ統合を促進しています。これらの技術革新が相まって、従来の診断アプローチから、より個別化され、予測的で、予防的ながん治療モデルへのシフトが推進されています。

がん生検の世界の需要を形成している地域的・疫学的要因とは？

がん生検の需要は、地域のヘルスケア能力、がん罹患パターン、早期発見を目的とした公衆衛生イニシアチブの組み合わせによって影響を受けます。北米と欧州では、先進的なヘルスケアインフラ、広範ながん検診プログラム、高い意識レベルが、乳がん、肺がん、大腸がん、前立腺がんなどの多様ながん種における生検の大量実施に寄与しています。これらの地域では早期発見が重視されており、保険適用や償還の仕組みも相まって、従来の生検法と先進的な生検法の両方が広く利用されています。アジア太平洋地域では、高齢化、喫煙率の増加、ライフスタイルの変化によるがん罹患率の上昇が、生検サービスの拡大を促進しています。中国、インド、日本のような国々は診断インフラに多額の投資を行っており、病理検査室、画像診断センター、腫瘍学サービスへのアクセスを拡大しています。がんの早期発見を促進する公衆衛生キャンペーンや移動診断装置の開発により、農村部や十分なサービスを受けていない地域での普及が進んでいます。ラテンアメリカやアフリカでは、専門的ヘルスケアへのアクセスが限られていることが依然として課題であるが、パートナーシップ、ドナー資金によるイニシアティブ、政府支援による検診プログラムを通じて、がん診断能力を向上させる取り組みが進行中です。これらの地域の都市センターでは、リキッドバイオプシーや分子プロファイリングを含む高度な診断方法に対する需要が高まっています。世界的には、集学的がん治療の台頭と生検のデジタルカルテへの統合が診断経路を合理化し、早期介入を促しています。アフリカやアジアの一部で子宮頸がん罹患率が高いことや、東南アジアの肝臓がんホットスポットなど、がん罹患率の地域差も、生検の実施や状況に応じたプロトコルの開発を形成しています。これらの動向は、医療制度ががんの転帰改善における生検の中心的役割を認識するにつれて、生検の利用が世界的に急増することを示しています。

がん生検市場の世界的拡大を促進する主な要因は何か？

がん生検市場の成長は、技術の進化、疫学動向、ヘルスケア政策、精密診断に対する臨床需要など、さまざまな要因によってもたらされます。最も重要な促進要因の一つは、世界のがん罹患率の上昇であり、悪性腫瘍を確認し治療を開始するための正確でタイムリーな診断ツールの必要性が高まっています。がんが世界の死亡原因の上位を占める中、信頼性の高い生検技術による早期発見の緊急性は先進国、発展途上国を問わず高まっています。細針吸引、コアニードル生検、リキッドバイオプシーなど、低侵襲・非侵襲の生検法の選択肢が広がり、患者へのアクセスが拡大し、手技に関連するリスクが低減しています。ゲノムシークエンシング、バイオマーカー探索、リアルタイムイメージングの技術的進歩により、生検は組織学的データだけでなく、標的治療や個別化治療計画の指針となる深い分子的洞察を提供できるようになっています。コンパニオン診断と標的薬剤の規制当局による承認が重視されるようになっていることは、生検による正確な腫瘍プロファイリングの必要性と密接に関連しています。医療制度は、医療費の増加とインフラ開発に支えられ、生検サービスを検診プログラムやがん治療経路に組み込む傾向を強めています。さらに、より低侵襲で、より迅速で、より正確な診断を求める患者の要望が、医療提供者に高度な生検技術の導入を促しています。臨床研究や腫瘍学的臨床試験も、適格性スクリーニングや治療モニタリングのために組織採取を必要とする研究が増えるにつれて、生検需要を牽引しています。このような市場促進要因を総合すると、がん生検市場は堅調に拡大しており、最新のデータ主導型、患者中心のがん医療において生検が重要な役割を担っていることが明らかになります。

セグメント

製品タイプ（装置、キット＆消耗品、ソフトウェア＆バイオインフォマティクス、ニードルベース装置、真空支援装置、ガイダンスシステム）、手技（組織生検、リキッドバイオプシー）、がんタイプ（乳がん、肺がん、大腸がん、前立腺がん、子宮頸がん、その他のがんタイプ）、エンドユーザー（病院エンドユーザー、診断ラボエンドユーザー、外来手術センターエンドユーザー）

調査対象企業の例

• Agilent Technologies Inc.
• ANGLE plc
• Becton, Dickinson and Company
• Biocept Inc.
• Bio-Rad Laboratories Inc.
• Bio-Techne Corporation
• Danaher Corporation
• Exact Sciences Corporation
• F. Hoffmann-La Roche AG
• Guardant Health Inc.
• Hologic Inc.
• Illumina Inc.
• Invitae Corporation
• Johnson & Johnson（Veridex）
• Leica Biosystems
• Menarini Silicon Biosystems
• Myriad Genetics Inc.
• Qiagen N.V.
• Thermo Fisher Scientific Inc.
• Veracyte Inc.

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家からキュレートされたコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Cancer Biopsies Market to Reach US$50.9 Billion by 2030

The global market for Cancer Biopsies estimated at US$29.0 Billion in the year 2024, is expected to reach US$50.9 Billion by 2030, growing at a CAGR of 9.8% over the analysis period 2024-2030. Instruments, one of the segments analyzed in the report, is expected to record a 8.6% CAGR and reach US$14.0 Billion by the end of the analysis period. Growth in the Kits & Consumables segment is estimated at 8.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$7.9 Billion While China is Forecast to Grow at 13.2% CAGR

The Cancer Biopsies market in the U.S. is estimated at US$7.9 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$10.2 Billion by the year 2030 trailing a CAGR of 13.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.2% and 8.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.7% CAGR.

Global Cancer Biopsies Market - Key Trends & Drivers Summarized

Why Are Cancer Biopsies Indispensable to Accurate Diagnosis and Personalized Treatment?

Cancer biopsies are critical procedures in modern oncology, serving as the definitive method for diagnosing cancer, determining tumor type, stage, and grade, and guiding personalized treatment plans. A biopsy involves the extraction of tissue or cells from a suspicious mass, followed by microscopic examination to detect malignancy and assess specific molecular markers. This diagnostic process not only confirms the presence of cancer but also provides essential insights into the tumor’s biological behavior and genetic profile. As cancer treatment increasingly shifts toward targeted therapies and immunotherapies, precise biopsy data is becoming even more vital. Physicians rely on biopsy results to select the most effective treatment protocols based on an individual’s tumor characteristics, ensuring that therapy is both appropriate and potentially more successful. Without a biopsy, treatment decisions would often be based on imaging and symptoms alone, which can be inconclusive or misleading. Moreover, biopsies are frequently used to monitor treatment response and detect cancer recurrence, making them a cornerstone of long-term patient management. Advances in pathology, imaging-guided techniques, and molecular testing have significantly improved the accuracy and safety of biopsy procedures. As cancer incidence rises globally, driven by aging populations, lifestyle changes, and environmental exposures, the need for early and accurate diagnosis through biopsies is growing more urgent, reinforcing their role as an irreplaceable element in the continuum of cancer care.

How Are Technological Innovations Transforming Biopsy Techniques and Diagnostic Precision?

The field of cancer biopsies is being revolutionized by a wave of technological advancements that are enhancing precision, minimizing invasiveness, and enabling real-time diagnostics. One of the most significant developments is the rise of image-guided biopsy techniques, such as ultrasound-guided, CT-guided, and MRI-guided biopsies, which allow clinicians to target tumors with exceptional accuracy, even in anatomically complex or deep-seated locations. These methods reduce procedural risks and increase diagnostic yield by ensuring that the most representative tissue is sampled. Another major innovation is the growth of liquid biopsies, which involve analyzing biomarkers such as circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and exosomes in blood or other body fluids. This non-invasive approach enables earlier detection, dynamic monitoring of treatment response, and identification of resistance mutations, all without the need for repeated tissue sampling. Next-generation sequencing (NGS) and other molecular profiling tools are also transforming how biopsy samples are analyzed, allowing for comprehensive genomic mapping of tumors and uncovering actionable mutations that can inform precision therapies. Robotic and AI-assisted biopsy devices are beginning to emerge, offering improved targeting and reduced variability between operators. Additionally, digital pathology is streamlining the review of biopsy slides, facilitating faster diagnoses, remote consultations, and data integration across cancer centers. Together, these innovations are driving a shift from conventional diagnostic approaches toward a more personalized, predictive, and preventive model of cancer care, where biopsies not only detect disease but also guide its management with increasing sophistication.

What Regional and Epidemiological Factors Are Shaping the Global Demand for Cancer Biopsies?

The demand for cancer biopsies is influenced by a combination of regional healthcare capacities, cancer incidence patterns, and public health initiatives aimed at early detection. In North America and Europe, advanced healthcare infrastructure, widespread cancer screening programs, and high awareness levels contribute to a high volume of biopsy procedures across diverse cancer types such as breast, lung, colorectal, and prostate cancers. The emphasis on early detection in these regions, coupled with insurance coverage and reimbursement mechanisms, supports widespread use of both traditional and advanced biopsy methods. In Asia-Pacific, rising cancer incidence due to aging populations, increased smoking rates, and lifestyle transitions is driving the expansion of biopsy services. Countries like China, India, and Japan are investing heavily in diagnostic infrastructure, expanding access to pathology labs, imaging centers, and oncology services. Public health campaigns promoting early cancer detection and the development of mobile diagnostic units are improving reach in rural and underserved areas. In Latin America and Africa, limited access to specialized healthcare remains a challenge, but efforts are underway to increase cancer diagnostic capabilities through partnerships, donor-funded initiatives, and government-supported screening programs. Urban centers in these regions are seeing growing demand for advanced diagnostic modalities, including liquid biopsies and molecular profiling. Globally, the rise of multidisciplinary cancer care and the integration of biopsies into digital health records are streamlining diagnostic pathways and encouraging early intervention. Regional variations in cancer prevalence, such as higher cervical cancer rates in parts of Africa and Asia or liver cancer hotspots in Southeast Asia, are also shaping biopsy practices and the development of context-specific protocols. These trends point to a global surge in biopsy utilization, as health systems recognize their central role in improving cancer outcomes.

What Are the Key Factors Driving the Global Expansion of the Cancer Biopsies Market?

The growth in the cancer biopsies market is driven by a constellation of factors that span technological evolution, epidemiological trends, healthcare policy, and clinical demand for precision diagnostics. One of the most significant drivers is the global rise in cancer incidence, which is increasing the need for accurate and timely diagnostic tools to confirm malignancy and initiate treatment. With cancer being a leading cause of mortality worldwide, the urgency for early detection through reliable biopsy techniques is intensifying across both developed and developing nations. The expanding availability of minimally invasive and non-invasive biopsy options, including fine-needle aspiration, core needle biopsies, and liquid biopsies, is broadening patient access and reducing procedure-related risks. Technological progress in genomic sequencing, biomarker discovery, and real-time imaging is allowing biopsies to provide not just histological data but also deep molecular insights that guide targeted therapies and personalized treatment plans. The growing emphasis on companion diagnostics and regulatory approvals for targeted drugs is tightly linked to the need for precise tumor profiling via biopsies. Health systems are increasingly integrating biopsy services into screening programs and cancer care pathways, supported by rising healthcare expenditure and infrastructure development. Additionally, patient demand for less invasive, faster, and more accurate diagnostic experiences is prompting providers to adopt advanced biopsy techniques. Clinical research and oncology trials are also driving biopsy demand as more studies require tissue sampling for eligibility screening and therapeutic monitoring. Together, these drivers reflect a robust and expanding market for cancer biopsies, underscoring their foundational role in modern, data-driven, and patient-centric cancer care.

SCOPE OF STUDY:

The report analyzes the Cancer Biopsies market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices, Guidance Systems); Procedure (Tissue Biopsy, Liquid Biopsy) Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer, Other Cancer Types); End User (Hospitals End User, Diagnostic Laboratories End User, Ambulatory Surgical Centers End User)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

• Agilent Technologies Inc.
• ANGLE plc
• Becton, Dickinson and Company
• Biocept Inc.
• Bio-Rad Laboratories Inc.
• Bio-Techne Corporation
• Danaher Corporation
• Exact Sciences Corporation
• F. Hoffmann-La Roche AG
• Guardant Health Inc.
• Hologic Inc.
• Illumina Inc.
• Invitae Corporation
• Johnson & Johnson (Veridex)
• Leica Biosystems
• Menarini Silicon Biosystems
• Myriad Genetics Inc.
• Qiagen N.V.
• Thermo Fisher Scientific Inc.
• Veracyte Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Cancer Biopsies - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Global Cancer Incidence Throws the Spotlight on Timely and Accurate Biopsy Diagnostics
  • Growing Shift Toward Precision Medicine Spurs Demand for Molecularly Guided Cancer Biopsies
  • Here's the Story: How Liquid Biopsies Are Transforming Early Detection and Monitoring of Cancer
  • Expansion of Targeted Therapies Strengthens Business Case for High-Resolution Tissue Sampling Technologies
  • Technological Innovations in Image-Guided and Minimally Invasive Biopsy Techniques Drive Market Adoption
  • Increased Use of Next-Generation Sequencing (NGS) in Oncology Generates Demand for High-Quality Biopsy Samples
  • Here's How Companion Diagnostics and Biomarker Discovery Are Shaping the Future of Cancer Biopsy Testing
  • Integration of AI and Digital Pathology Enhances Speed, Accuracy, and Scalability of Biopsy Result Interpretation
  • Growing Preference for Outpatient and Ambulatory Procedures Fuels Demand for Portable and Less-Invasive Biopsy Devices
  • Rising Emphasis on Repeat Biopsies for Treatment Monitoring Expands Opportunities in Longitudinal Cancer Care
  • Public and Private Investment in Cancer Screening Programs Drives Volume Demand for Diagnostic Biopsies
  • Increased Focus on Rare and Hard-to-Biopsy Cancers Spurs Development of Novel Sampling Methods and Devices
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Cancer Biopsies Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Cancer Biopsies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Cancer Biopsies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 4: World 16-Year Perspective for Cancer Biopsies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 7: World 16-Year Perspective for Instruments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Kits & Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Kits & Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 10: World 16-Year Perspective for Kits & Consumables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Software & Bioinformatics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Software & Bioinformatics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 13: World 16-Year Perspective for Software & Bioinformatics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Needle-based Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Needle-based Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 16: World 16-Year Perspective for Needle-based Devices by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Vacuum-assisted Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Vacuum-assisted Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 19: World 16-Year Perspective for Vacuum-assisted Devices by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Guidance Systems by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Guidance Systems by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 22: World 16-Year Perspective for Guidance Systems by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Diagnostic Laboratories End User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Diagnostic Laboratories End User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 25: World 16-Year Perspective for Diagnostic Laboratories End User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Ambulatory Surgical Centers End User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Ambulatory Surgical Centers End User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 28: World 16-Year Perspective for Ambulatory Surgical Centers End User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Hospitals End User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Hospitals End User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 31: World 16-Year Perspective for Hospitals End User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Tissue Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Tissue Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 34: World 16-Year Perspective for Tissue Biopsy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Liquid Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Liquid Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 37: World 16-Year Perspective for Liquid Biopsy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Cancer Biopsies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 38: USA Recent Past, Current & Future Analysis for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 40: USA 16-Year Perspective for Cancer Biopsies by Product - Percentage Breakdown of Value Sales for Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems for the Years 2014, 2025 & 2030
  • TABLE 41: USA Recent Past, Current & Future Analysis for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 43: USA 16-Year Perspective for Cancer Biopsies by End User - Percentage Breakdown of Value Sales for Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User for the Years 2014, 2025 & 2030
  • TABLE 44: USA Recent Past, Current & Future Analysis for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 46: USA 16-Year Perspective for Cancer Biopsies by Procedure - Percentage Breakdown of Value Sales for Tissue Biopsy and Liquid Biopsy for the Years 2014, 2025 & 2030
• CANADA
  • TABLE 47: Canada Recent Past, Current & Future Analysis for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Canada Historic Review for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 49: Canada 16-Year Perspective for Cancer Biopsies by Product - Percentage Breakdown of Value Sales for Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems for the Years 2014, 2025 & 2030
  • TABLE 50: Canada Recent Past, Current & Future Analysis for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 52: Canada 16-Year Perspective for Cancer Biopsies by End User - Percentage Breakdown of Value Sales for Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User for the Years 2014, 2025 & 2030
  • TABLE 53: Canada Recent Past, Current & Future Analysis for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Canada Historic Review for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 55: Canada 16-Year Perspective for Cancer Biopsies by Procedure - Percentage Breakdown of Value Sales for Tissue Biopsy and Liquid Biopsy for the Years 2014, 2025 & 2030
• JAPAN
  • Cancer Biopsies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 56: Japan Recent Past, Current & Future Analysis for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Japan Historic Review for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 58: Japan 16-Year Perspective for Cancer Biopsies by Product - Percentage Breakdown of Value Sales for Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems for the Years 2014, 2025 & 2030
  • TABLE 59: Japan Recent Past, Current & Future Analysis for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Japan Historic Review for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 61: Japan 16-Year Perspective for Cancer Biopsies by End User - Percentage Breakdown of Value Sales for Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User for the Years 2014, 2025 & 2030
  • TABLE 62: Japan Recent Past, Current & Future Analysis for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Japan Historic Review for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 64: Japan 16-Year Perspective for Cancer Biopsies by Procedure - Percentage Breakdown of Value Sales for Tissue Biopsy and Liquid Biopsy for the Years 2014, 2025 & 2030
• CHINA
  • Cancer Biopsies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 65: China Recent Past, Current & Future Analysis for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: China Historic Review for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 67: China 16-Year Perspective for Cancer Biopsies by Product - Percentage Breakdown of Value Sales for Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems for the Years 2014, 2025 & 2030
  • TABLE 68: China Recent Past, Current & Future Analysis for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: China Historic Review for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 70: China 16-Year Perspective for Cancer Biopsies by End User - Percentage Breakdown of Value Sales for Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User for the Years 2014, 2025 & 2030
  • TABLE 71: China Recent Past, Current & Future Analysis for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: China Historic Review for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 73: China 16-Year Perspective for Cancer Biopsies by Procedure - Percentage Breakdown of Value Sales for Tissue Biopsy and Liquid Biopsy for the Years 2014, 2025 & 2030
• EUROPE
  • Cancer Biopsies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 74: Europe Recent Past, Current & Future Analysis for Cancer Biopsies by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for Cancer Biopsies by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 76: Europe 16-Year Perspective for Cancer Biopsies by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 79: Europe 16-Year Perspective for Cancer Biopsies by Product - Percentage Breakdown of Value Sales for Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems for the Years 2014, 2025 & 2030
  • TABLE 80: Europe Recent Past, Current & Future Analysis for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Europe Historic Review for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 82: Europe 16-Year Perspective for Cancer Biopsies by End User - Percentage Breakdown of Value Sales for Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User for the Years 2014, 2025 & 2030
  • TABLE 83: Europe Recent Past, Current & Future Analysis for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Europe Historic Review for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 85: Europe 16-Year Perspective for Cancer Biopsies by Procedure - Percentage Breakdown of Value Sales for Tissue Biopsy and Liquid Biopsy for the Years 2014, 2025 & 2030
• FRANCE
  • Cancer Biopsies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 86: France Recent Past, Current & Future Analysis for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: France Historic Review for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 88: France 16-Year Perspective for Cancer Biopsies by Product - Percentage Breakdown of Value Sales for Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems for the Years 2014, 2025 & 2030
  • TABLE 89: France Recent Past, Current & Future Analysis for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: France Historic Review for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 91: France 16-Year Perspective for Cancer Biopsies by End User - Percentage Breakdown of Value Sales for Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User for the Years 2014, 2025 & 2030
  • TABLE 92: France Recent Past, Current & Future Analysis for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: France Historic Review for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 94: France 16-Year Perspective for Cancer Biopsies by Procedure - Percentage Breakdown of Value Sales for Tissue Biopsy and Liquid Biopsy for the Years 2014, 2025 & 2030
• GERMANY
  • Cancer Biopsies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 95: Germany Recent Past, Current & Future Analysis for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Germany Historic Review for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 97: Germany 16-Year Perspective for Cancer Biopsies by Product - Percentage Breakdown of Value Sales for Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems for the Years 2014, 2025 & 2030
  • TABLE 98: Germany Recent Past, Current & Future Analysis for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Germany Historic Review for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 100: Germany 16-Year Perspective for Cancer Biopsies by End User - Percentage Breakdown of Value Sales for Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User for the Years 2014, 2025 & 2030
  • TABLE 101: Germany Recent Past, Current & Future Analysis for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Germany Historic Review for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 103: Germany 16-Year Perspective for Cancer Biopsies by Procedure - Percentage Breakdown of Value Sales for Tissue Biopsy and Liquid Biopsy for the Years 2014, 2025 & 2030
• ITALY
  • TABLE 104: Italy Recent Past, Current & Future Analysis for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Italy Historic Review for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 106: Italy 16-Year Perspective for Cancer Biopsies by Product - Percentage Breakdown of Value Sales for Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems for the Years 2014, 2025 & 2030
  • TABLE 107: Italy Recent Past, Current & Future Analysis for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Italy Historic Review for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 109: Italy 16-Year Perspective for Cancer Biopsies by End User - Percentage Breakdown of Value Sales for Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User for the Years 2014, 2025 & 2030
  • TABLE 110: Italy Recent Past, Current & Future Analysis for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Italy Historic Review for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 112: Italy 16-Year Perspective for Cancer Biopsies by Procedure - Percentage Breakdown of Value Sales for Tissue Biopsy and Liquid Biopsy for the Years 2014, 2025 & 2030
• UNITED KINGDOM
  • Cancer Biopsies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 113: UK Recent Past, Current & Future Analysis for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: UK Historic Review for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 115: UK 16-Year Perspective for Cancer Biopsies by Product - Percentage Breakdown of Value Sales for Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems for the Years 2014, 2025 & 2030
  • TABLE 116: UK Recent Past, Current & Future Analysis for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: UK Historic Review for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 118: UK 16-Year Perspective for Cancer Biopsies by End User - Percentage Breakdown of Value Sales for Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User for the Years 2014, 2025 & 2030
  • TABLE 119: UK Recent Past, Current & Future Analysis for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: UK Historic Review for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 121: UK 16-Year Perspective for Cancer Biopsies by Procedure - Percentage Breakdown of Value Sales for Tissue Biopsy and Liquid Biopsy for the Years 2014, 2025 & 2030
• SPAIN
  • TABLE 122: Spain Recent Past, Current & Future Analysis for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Spain Historic Review for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 124: Spain 16-Year Perspective for Cancer Biopsies by Product - Percentage Breakdown of Value Sales for Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems for the Years 2014, 2025 & 2030
  • TABLE 125: Spain Recent Past, Current & Future Analysis for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Spain Historic Review for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 127: Spain 16-Year Perspective for Cancer Biopsies by End User - Percentage Breakdown of Value Sales for Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User for the Years 2014, 2025 & 2030
  • TABLE 128: Spain Recent Past, Current & Future Analysis for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Spain Historic Review for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 130: Spain 16-Year Perspective for Cancer Biopsies by Procedure - Percentage Breakdown of Value Sales for Tissue Biopsy and Liquid Biopsy for the Years 2014, 2025 & 2030
• RUSSIA
  • TABLE 131: Russia Recent Past, Current & Future Analysis for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Russia Historic Review for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 133: Russia 16-Year Perspective for Cancer Biopsies by Product - Percentage Breakdown of Value Sales for Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems for the Years 2014, 2025 & 2030
  • TABLE 134: Russia Recent Past, Current & Future Analysis for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Russia Historic Review for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 136: Russia 16-Year Perspective for Cancer Biopsies by End User - Percentage Breakdown of Value Sales for Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User for the Years 2014, 2025 & 2030
  • TABLE 137: Russia Recent Past, Current & Future Analysis for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Russia Historic Review for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 139: Russia 16-Year Perspective for Cancer Biopsies by Procedure - Percentage Breakdown of Value Sales for Tissue Biopsy and Liquid Biopsy for the Years 2014, 2025 & 2030
• REST OF EUROPE
  • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Rest of Europe Historic Review for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 142: Rest of Europe 16-Year Perspective for Cancer Biopsies by Product - Percentage Breakdown of Value Sales for Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems for the Years 2014, 2025 & 2030
  • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Rest of Europe Historic Review for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 145: Rest of Europe 16-Year Perspective for Cancer Biopsies by End User - Percentage Breakdown of Value Sales for Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User for the Years 2014, 2025 & 2030
  • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Rest of Europe Historic Review for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 148: Rest of Europe 16-Year Perspective for Cancer Biopsies by Procedure - Percentage Breakdown of Value Sales for Tissue Biopsy and Liquid Biopsy for the Years 2014, 2025 & 2030
• ASIA-PACIFIC
  • Cancer Biopsies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Cancer Biopsies by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 150: Asia-Pacific Historic Review for Cancer Biopsies by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 151: Asia-Pacific 16-Year Perspective for Cancer Biopsies by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 154: Asia-Pacific 16-Year Perspective for Cancer Biopsies by Product - Percentage Breakdown of Value Sales for Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems for the Years 2014, 2025 & 2030
  • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Asia-Pacific Historic Review for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 157: Asia-Pacific 16-Year Perspective for Cancer Biopsies by End User - Percentage Breakdown of Value Sales for Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User for the Years 2014, 2025 & 2030
  • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Asia-Pacific Historic Review for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 160: Asia-Pacific 16-Year Perspective for Cancer Biopsies by Procedure - Percentage Breakdown of Value Sales for Tissue Biopsy and Liquid Biopsy for the Years 2014, 2025 & 2030
• AUSTRALIA
  • Cancer Biopsies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 161: Australia Recent Past, Current & Future Analysis for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Australia Historic Review for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 163: Australia 16-Year Perspective for Cancer Biopsies by Product - Percentage Breakdown of Value Sales for Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems for the Years 2014, 2025 & 2030
  • TABLE 164: Australia Recent Past, Current & Future Analysis for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Australia Historic Review for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 166: Australia 16-Year Perspective for Cancer Biopsies by End User - Percentage Breakdown of Value Sales for Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User for the Years 2014, 2025 & 2030
  • TABLE 167: Australia Recent Past, Current & Future Analysis for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Australia Historic Review for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 169: Australia 16-Year Perspective for Cancer Biopsies by Procedure - Percentage Breakdown of Value Sales for Tissue Biopsy and Liquid Biopsy for the Years 2014, 2025 & 2030
• INDIA
  • Cancer Biopsies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 170: India Recent Past, Current & Future Analysis for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: India Historic Review for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 172: India 16-Year Perspective for Cancer Biopsies by Product - Percentage Breakdown of Value Sales for Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems for the Years 2014, 2025 & 2030
  • TABLE 173: India Recent Past, Current & Future Analysis for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: India Historic Review for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 175: India 16-Year Perspective for Cancer Biopsies by End User - Percentage Breakdown of Value Sales for Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User for the Years 2014, 2025 & 2030
  • TABLE 176: India Recent Past, Current & Future Analysis for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: India Historic Review for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 178: India 16-Year Perspective for Cancer Biopsies by Procedure - Percentage Breakdown of Value Sales for Tissue Biopsy and Liquid Biopsy for the Years 2014, 2025 & 2030
• SOUTH KOREA
  • TABLE 179: South Korea Recent Past, Current & Future Analysis for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: South Korea Historic Review for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 181: South Korea 16-Year Perspective for Cancer Biopsies by Product - Percentage Breakdown of Value Sales for Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems for the Years 2014, 2025 & 2030
  • TABLE 182: South Korea Recent Past, Current & Future Analysis for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: South Korea Historic Review for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 184: South Korea 16-Year Perspective for Cancer Biopsies by End User - Percentage Breakdown of Value Sales for Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User for the Years 2014, 2025 & 2030
  • TABLE 185: South Korea Recent Past, Current & Future Analysis for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: South Korea Historic Review for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 187: South Korea 16-Year Perspective for Cancer Biopsies by Procedure - Percentage Breakdown of Value Sales for Tissue Biopsy and Liquid Biopsy for the Years 2014, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Rest of Asia-Pacific Historic Review for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 190: Rest of Asia-Pacific 16-Year Perspective for Cancer Biopsies by Product - Percentage Breakdown of Value Sales for Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems for the Years 2014, 2025 & 2030
  • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Asia-Pacific Historic Review for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 193: Rest of Asia-Pacific 16-Year Perspective for Cancer Biopsies by End User - Percentage Breakdown of Value Sales for Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User for the Years 2014, 2025 & 2030
  • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Rest of Asia-Pacific Historic Review for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 196: Rest of Asia-Pacific 16-Year Perspective for Cancer Biopsies by Procedure - Percentage Breakdown of Value Sales for Tissue Biopsy and Liquid Biopsy for the Years 2014, 2025 & 2030
• LATIN AMERICA
  • Cancer Biopsies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 197: Latin America Recent Past, Current & Future Analysis for Cancer Biopsies by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 198: Latin America Historic Review for Cancer Biopsies by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 199: Latin America 16-Year Perspective for Cancer Biopsies by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 202: Latin America 16-Year Perspective for Cancer Biopsies by Product - Percentage Breakdown of Value Sales for Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems for the Years 2014, 2025 & 2030
  • TABLE 203: Latin America Recent Past, Current & Future Analysis for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Latin America Historic Review for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 205: Latin America 16-Year Perspective for Cancer Biopsies by End User - Percentage Breakdown of Value Sales for Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User for the Years 2014, 2025 & 2030
  • TABLE 206: Latin America Recent Past, Current & Future Analysis for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Latin America Historic Review for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 208: Latin America 16-Year Perspective for Cancer Biopsies by Procedure - Percentage Breakdown of Value Sales for Tissue Biopsy and Liquid Biopsy for the Years 2014, 2025 & 2030
• ARGENTINA
  • TABLE 209: Argentina Recent Past, Current & Future Analysis for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Argentina Historic Review for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 211: Argentina 16-Year Perspective for Cancer Biopsies by Product - Percentage Breakdown of Value Sales for Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems for the Years 2014, 2025 & 2030
  • TABLE 212: Argentina Recent Past, Current & Future Analysis for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Argentina Historic Review for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 214: Argentina 16-Year Perspective for Cancer Biopsies by End User - Percentage Breakdown of Value Sales for Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User for the Years 2014, 2025 & 2030
  • TABLE 215: Argentina Recent Past, Current & Future Analysis for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Argentina Historic Review for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 217: Argentina 16-Year Perspective for Cancer Biopsies by Procedure - Percentage Breakdown of Value Sales for Tissue Biopsy and Liquid Biopsy for the Years 2014, 2025 & 2030
• BRAZIL
  • TABLE 218: Brazil Recent Past, Current & Future Analysis for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Brazil Historic Review for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 220: Brazil 16-Year Perspective for Cancer Biopsies by Product - Percentage Breakdown of Value Sales for Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems for the Years 2014, 2025 & 2030
  • TABLE 221: Brazil Recent Past, Current & Future Analysis for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Brazil Historic Review for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 223: Brazil 16-Year Perspective for Cancer Biopsies by End User - Percentage Breakdown of Value Sales for Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User for the Years 2014, 2025 & 2030
  • TABLE 224: Brazil Recent Past, Current & Future Analysis for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Brazil Historic Review for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 226: Brazil 16-Year Perspective for Cancer Biopsies by Procedure - Percentage Breakdown of Value Sales for Tissue Biopsy and Liquid Biopsy for the Years 2014, 2025 & 2030
• MEXICO
  • TABLE 227: Mexico Recent Past, Current & Future Analysis for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Mexico Historic Review for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 229: Mexico 16-Year Perspective for Cancer Biopsies by Product - Percentage Breakdown of Value Sales for Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems for the Years 2014, 2025 & 2030
  • TABLE 230: Mexico Recent Past, Current & Future Analysis for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Mexico Historic Review for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 232: Mexico 16-Year Perspective for Cancer Biopsies by End User - Percentage Breakdown of Value Sales for Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User for the Years 2014, 2025 & 2030
  • TABLE 233: Mexico Recent Past, Current & Future Analysis for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Mexico Historic Review for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 235: Mexico 16-Year Perspective for Cancer Biopsies by Procedure - Percentage Breakdown of Value Sales for Tissue Biopsy and Liquid Biopsy for the Years 2014, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Rest of Latin America Historic Review for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 238: Rest of Latin America 16-Year Perspective for Cancer Biopsies by Product - Percentage Breakdown of Value Sales for Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems for the Years 2014, 2025 & 2030
  • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Latin America Historic Review for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 241: Rest of Latin America 16-Year Perspective for Cancer Biopsies by End User - Percentage Breakdown of Value Sales for Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User for the Years 2014, 2025 & 2030
  • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Rest of Latin America Historic Review for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 244: Rest of Latin America 16-Year Perspective for Cancer Biopsies by Procedure - Percentage Breakdown of Value Sales for Tissue Biopsy and Liquid Biopsy for the Years 2014, 2025 & 2030
• MIDDLE EAST
  • Cancer Biopsies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 245: Middle East Recent Past, Current & Future Analysis for Cancer Biopsies by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 246: Middle East Historic Review for Cancer Biopsies by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 247: Middle East 16-Year Perspective for Cancer Biopsies by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 250: Middle East 16-Year Perspective for Cancer Biopsies by Product - Percentage Breakdown of Value Sales for Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems for the Years 2014, 2025 & 2030
  • TABLE 251: Middle East Recent Past, Current & Future Analysis for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Middle East Historic Review for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 253: Middle East 16-Year Perspective for Cancer Biopsies by End User - Percentage Breakdown of Value Sales for Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User for the Years 2014, 2025 & 2030
  • TABLE 254: Middle East Recent Past, Current & Future Analysis for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Middle East Historic Review for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 256: Middle East 16-Year Perspective for Cancer Biopsies by Procedure - Percentage Breakdown of Value Sales for Tissue Biopsy and Liquid Biopsy for the Years 2014, 2025 & 2030
• IRAN
  • TABLE 257: Iran Recent Past, Current & Future Analysis for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Iran Historic Review for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 259: Iran 16-Year Perspective for Cancer Biopsies by Product - Percentage Breakdown of Value Sales for Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems for the Years 2014, 2025 & 2030
  • TABLE 260: Iran Recent Past, Current & Future Analysis for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Iran Historic Review for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 262: Iran 16-Year Perspective for Cancer Biopsies by End User - Percentage Breakdown of Value Sales for Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User for the Years 2014, 2025 & 2030
  • TABLE 263: Iran Recent Past, Current & Future Analysis for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Iran Historic Review for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 265: Iran 16-Year Perspective for Cancer Biopsies by Procedure - Percentage Breakdown of Value Sales for Tissue Biopsy and Liquid Biopsy for the Years 2014, 2025 & 2030
• ISRAEL
  • TABLE 266: Israel Recent Past, Current & Future Analysis for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Israel Historic Review for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 268: Israel 16-Year Perspective for Cancer Biopsies by Product - Percentage Breakdown of Value Sales for Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems for the Years 2014, 2025 & 2030
  • TABLE 269: Israel Recent Past, Current & Future Analysis for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Israel Historic Review for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 271: Israel 16-Year Perspective for Cancer Biopsies by End User - Percentage Breakdown of Value Sales for Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User for the Years 2014, 2025 & 2030
  • TABLE 272: Israel Recent Past, Current & Future Analysis for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Israel Historic Review for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 274: Israel 16-Year Perspective for Cancer Biopsies by Procedure - Percentage Breakdown of Value Sales for Tissue Biopsy and Liquid Biopsy for the Years 2014, 2025 & 2030
• SAUDI ARABIA
  • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Saudi Arabia Historic Review for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 277: Saudi Arabia 16-Year Perspective for Cancer Biopsies by Product - Percentage Breakdown of Value Sales for Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems for the Years 2014, 2025 & 2030
  • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Saudi Arabia Historic Review for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 280: Saudi Arabia 16-Year Perspective for Cancer Biopsies by End User - Percentage Breakdown of Value Sales for Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User for the Years 2014, 2025 & 2030
  • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Saudi Arabia Historic Review for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 283: Saudi Arabia 16-Year Perspective for Cancer Biopsies by Procedure - Percentage Breakdown of Value Sales for Tissue Biopsy and Liquid Biopsy for the Years 2014, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 284: UAE Recent Past, Current & Future Analysis for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: UAE Historic Review for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 286: UAE 16-Year Perspective for Cancer Biopsies by Product - Percentage Breakdown of Value Sales for Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems for the Years 2014, 2025 & 2030
  • TABLE 287: UAE Recent Past, Current & Future Analysis for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: UAE Historic Review for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 289: UAE 16-Year Perspective for Cancer Biopsies by End User - Percentage Breakdown of Value Sales for Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User for the Years 2014, 2025 & 2030
  • TABLE 290: UAE Recent Past, Current & Future Analysis for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: UAE Historic Review for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 292: UAE 16-Year Perspective for Cancer Biopsies by Procedure - Percentage Breakdown of Value Sales for Tissue Biopsy and Liquid Biopsy for the Years 2014, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Rest of Middle East Historic Review for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 295: Rest of Middle East 16-Year Perspective for Cancer Biopsies by Product - Percentage Breakdown of Value Sales for Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems for the Years 2014, 2025 & 2030
  • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Rest of Middle East Historic Review for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 298: Rest of Middle East 16-Year Perspective for Cancer Biopsies by End User - Percentage Breakdown of Value Sales for Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User for the Years 2014, 2025 & 2030
  • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Rest of Middle East Historic Review for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 301: Rest of Middle East 16-Year Perspective for Cancer Biopsies by Procedure - Percentage Breakdown of Value Sales for Tissue Biopsy and Liquid Biopsy for the Years 2014, 2025 & 2030
• AFRICA
  • Cancer Biopsies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 302: Africa Recent Past, Current & Future Analysis for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Africa Historic Review for Cancer Biopsies by Product - Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 304: Africa 16-Year Perspective for Cancer Biopsies by Product - Percentage Breakdown of Value Sales for Instruments, Kits & Consumables, Software & Bioinformatics, Needle-based Devices, Vacuum-assisted Devices and Guidance Systems for the Years 2014, 2025 & 2030
  • TABLE 305: Africa Recent Past, Current & Future Analysis for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Africa Historic Review for Cancer Biopsies by End User - Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 307: Africa 16-Year Perspective for Cancer Biopsies by End User - Percentage Breakdown of Value Sales for Diagnostic Laboratories End User, Ambulatory Surgical Centers End User and Hospitals End User for the Years 2014, 2025 & 2030
  • TABLE 308: Africa Recent Past, Current & Future Analysis for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Africa Historic Review for Cancer Biopsies by Procedure - Tissue Biopsy and Liquid Biopsy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 310: Africa 16-Year Perspective for Cancer Biopsies by Procedure - Percentage Breakdown of Value Sales for Tissue Biopsy and Liquid Biopsy for the Years 2014, 2025 & 2030

IV. COMPETITION